论文部分内容阅读
CD133(prominin-1)是5次跨膜(5-TM)糖蛋白家族中的第1个成员,这种蛋白局限性分布于胞质膜的突出处。人CD133分子存在2种亚型:CD133-1和CD133-2。作为肿瘤干细胞表面标志之一的CD133分子,它可以联合其他组织特异性、细胞特异性的分子进行肿瘤干细胞的筛选,其抗原位点可能会成为肿瘤治疗的靶位点。CD133为寻找神经胶质瘤干细胞特异标志物提供重要线索,是现在分离、纯化神经胶质瘤干细胞最重要的标志物,为肿瘤的发生、发展和预后的判断提供重要线索。但是,CD133作为神经胶质瘤干细胞特异性标志物的可靠性仍颇受争议。本文就近年来CD133的研究现状及其与神经胶质瘤相关性予以综述。
CD133 (prominin-1) is the first member of the 5-transmembrane (5-TM) glycoprotein family that is localized to the prominence of the cytoplasmic membrane. There are two subtypes of human CD133 molecules: CD133-1 and CD133-2. CD133, one of the surface markers of cancer stem cells, can be used in combination with other tissue-specific and cell-specific molecules to screen cancer stem cells, and its antigenic site may be the target of tumor therapy. CD133 is an important clue for finding specific markers of glioma stem cells, which is the most important marker for isolating and purifying glioma stem cells now. It provides important clues for the occurrence, development and prognosis of glioma. However, the reliability of CD133 as a specific marker of glioma stem cells remains controversial. This article reviews the status of CD133 in recent years and its relationship with glioma.